The recent paper by Ballen et al 1 adds to the literature 2 on autologous stem cell transplantation in patients unwilling to receive either donated or pre-deposited autologous blood products. As pointed out by the author, the safety of autologous transplantation in such a group remains uncertain due to the paucity of reports in the literature. We would like to report a case of a relatively complicated autologous PBSC transplant in a Jehovah's Witness. The patient, a 47-year-old male, was diagnosed with follicular lymphoma in 1998 having presented with widespread para-aortic lymphadenopathy and a right-sided hydronephrosis. Despite initial treatment with radiotherapy and CHOP chemotherapy, he relapsed 1 year later and was unresponsive to pulsed chlorambucil therapy.
Following a course of anti-CD20 (Mabthera, Roche, UK) therapy, to which a partial response was obtained, he was referred for consideration of high-dose chemotherapy. The patient was counselled and the increased risks of the procedure, particularly haemorrhagic complications arising from the patients' decision not to receive blood product support, were explained. The case was discussed with the Hospital Risk Management Committee who advised that the patient should be specifically advised of the risk of nonfatal cerebral haemorrhage with permanent neurological sequelae and disability.
Following further detailed discussions with the patient and his wife (also a Jehovah's Witness) we undertook PBSC mobilisation with G-CSF (10 g/kg per day) which led to the collection of a total of 3 × 10 6 /kg CD34 + cells in four aphereses. A femoral Hickman line had been inserted for this purpose without complication. As our target number of CD34 + cells for autologous PBSC transplant is Ͼ5 × 10 6 /kg, 3 and because we wanted a higher CD34 + cell number in this patient to ensure rapid haemopoietic recovery, we repeated the PBSC mobilisation using IVE and G-CSF as previously described. 3 This resulted in the collection of 2.45 × 10 6 /kg CD34 + cells in a further three aphereses.
During this period the patient received erythropoietin at a dose of 10 000 IU s.c. three times per week. Following the second PBSC mobilisation the patient was admitted in February 2000 for high-dose chemotherapy with the BEAM regimen. At this time his FBC showed Hb 11.5 gm/dl, platelets 323 × 10 9 /l and WCC 5.05 × 10 9 /l (ANC 3.19 × 10 9 /l). PBSCs from both mobilisation procedures were
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Sefcick and colleagues report another case of autologous transplant without the use of any blood products. In this patient, the course was complicated by staphylococcal bacteremia, anemia and thrombocytopenia. Fortunately, infused over 2 days, ie a total of 5.45 × 10 6 /kg CD34 + cells. Post transplant, the patient received oral ferrous sulphate, erythropoietin 10,000 IU s.c. daily and G-CSF 300 g s.c. daily. At day +6 post transplant, he spiked a fever to 39.5°C and became hypotensive requiring colloid infusions to support his blood pressure, as well as treatment with broad-spectrum antibiotics. Staphylococcus epidermidis was later isolated from both peripheral and central line cultures.
By day +8 the fever had resolved, but the Hb had fallen to 6.9 g/dl with platelets reaching a nadir of 6 × 10 9 /l. This was associated with widespread purpura but no mucosal or retinal haemorrhages. The patient engrafted reaching an ANC of Ͼ0.5 × 10 9 /l at day +10 and platelets of Ͼ20 × 10 9 /l at day +12. The haemoglobin rapidly recovered reaching 9.8 g/dl by discharge on day +14 and 11.9 g/dl by day +17 post transplant. A repeat CT scan at 3 months post transplant has shown complete resolution of the lymphadenopathy.
In this patient the post-transplant course was complicated by a septicaemic episode which may have resulted in a greater fall in the haemoglobin than expected, but as in the other cases described, platelet counts below an accepted trigger point for platelet transfusion (10 × 10 9 /l) were recorded and the patient developed extensive purpura.
Although the use of erythropoietin was successful in obviating the need for red cell infusions, it is important that patients wishing to proceed with bloodless transplants are made well aware by their transplant team of the additional risks, particularly the risks of serious haemorrhage, under which they place themselves.
the patient did not have any bleeding complications and no transfusions were administered. This report, as well as the one cited by our group and others, 1, 2 suggest that autologous transplantation can be taken without the use of any blood products. We agree that the patient needs to be duly informed of the increased risk with this approach.
